BioNTech
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
Overall, against moderate-severe COVID-19 infection, the vaccine was 72% effective 28 days after vaccination in the U.S., 66% in hard-hit Latin America, and bottomed out at 57% in South Africa.
The pharmaceutical industry continues to demonstrate its willingness to team up in the ongoing combat against the global COVID-19 pandemic.
The data is continuing to come in on the various COVID-19 variants, and so far the news is pretty good.
Much of the attention on Pfizer, BioNTech, Moderna, Johnson & Johnson and AstraZeneca for the last few months has been on their COVID-19 vaccine efforts.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 26, 2021.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.
Pfizer and BioNTech announced that their COVID-19 vaccine was probably just as effective against the variant strain of the virus, B.1.1.7, found in the U.K.
JOBS
IN THE PRESS